Newsroom

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Feb. 7, 2012– AVEO Pharmaceuticals, Inc. (Nasdaq: AVEO) today announced that financial results for the company’s fourth quarter and year ended December 31, 2011 will be released before the market opens on Tuesday, February 14, 2012. The AVEO management team will host a conference call discussing the company’s financial results, recent developments and 2012 guidance on Tuesday,

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Feb. 2, 2012– AVEO Pharmaceuticals, Inc. (Nasdaq: AVEO) today announced that members of the company’s management team are scheduled to present a corporate overview at several upcoming investment conferences. The conference and AVEO presentation details are as follows: Webcasts of AVEO’s presentations can be accessed by visiting the investors section of the company’s

Download PDF TIVO-1 is the First Registration Trial to Compare an Investigational Agent to an Approved VEGF Therapy in First-line RCC AVEO Conference Call Today at 8:30 a.m. ET CAMBRIDGE, Mass. & TOKYO–(BUSINESS WIRE)–Jan. 3, 2012– AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) and Astellas Pharma Inc. (TSE: 4503) today announced that tivozanib demonstrated superiority over sorafenib in the primary endpoint of progression-free survival

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jan. 2, 2012– AVEO Pharmaceuticals, Inc. (Nasdaq: AVEO) today announced that the AVEO management team will host a conference call on Tuesday, January 3, 2012 at 8:30 a.m. (ET). The call can be accessed by dialing 1-866-825-3354 (domestic) or 1-617-213-8063 (international) five minutes prior to the start of the call and providing the passcode 17542026. A

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Dec. 28, 2011– AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that Tuan Ha-Ngoc, president and chief executive officer, is scheduled to present at the 30th Annual J.P. Morgan Healthcare Conference onTuesday, January 10, 2012 at 11:30 a.m. (PST) at the Westin St. Francis Hotel in San Francisco. A live webcast of AVEO’s presentation can be accessed by visiting the investors section of

Download PDF The Trial, BATON-CRC, is Second in Series of Tivozanib Biomarker Trials CAMBRIDGE, MASS.–(BUSINESS WIRE)–Dec. 22, 2011– AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced the initiation of patient enrollment in an open-label, multicenter, randomized Phase 2 clinical trial, called BATON-CRC, evaluating tivozanib in combination with modified FOLFOX6 (mFOLFOX6) compared to bevacizumab in combination with mFOLFOX6 as

Download PDF CAMBRIDGE, Mass. & INGELHEIM, Germany–(BUSINESS WIRE)–Dec. 1, 2011– AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) and Boehringer Ingelheim today announced that they have entered into an agreement for large-scale process development and clinical manufacturing of ficlatuzumab, AVEO’s novel HGF inhibitory antibody that is currently in Phase 2 clinical development in patients with non-small cell lung cancer (NSCLC). Boehringer Ingelheim

Download PDF Tivozanib Highlighted at EMUC 2011; New Data Featured at AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference CAMBRIDGE, Mass., Nov 03, 2011 (BUSINESS WIRE) — AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that previously reported clinical data evaluating its lead product candidate tivozanib will be featured at the 3rd European Multidisciplinary Meeting on Urological Cancers